Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Overview of attention for article published in Blood Advances, August 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 10 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 36 Mendeley

So far, Altmetric has seen 11 X posts from 10 X users, with an upper bound of 31,792 followers.

RT @AlkaliDr: #Ivosidenib in r/r #MDS with #IDH1m ⭐️ 38.9% CR+PR ⭐️ 83.3% ORR ⭐️ mOS 35.7m ⭐️ 10.5% DS 👀 @BloodAdvances Final phase…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.